Cephalon seeks additional approval for cancer pain treatment

11/13/2007 | American City Business Journals

Cephalon is requesting expanded FDA approval for the use of its "breakthrough pain" cancer drug Fentora in opioid-tolerant patients suffering from chronic pain. The company and the FDA previously issued warnings about the potential fatal risk linked to the misuse of Fentora, but the company said at that time it was working with the agency on revised patient selection criteria and dosing instructions for the drug's packaging.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN